QSI

EX-99.1

2 qsi8132026ex991.htm

EX-99.1

Document

Exhibit 99.1

Quantum-Si Reports Second Quarter 2026 Financial Results and

Provides Proteus™ Development Update

Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing

BRANFORD, Conn. -- (GLOBE NEWSWIRE) -- August 13, 2026 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced financial results for the second quarter ended June 30, 2026.

Press Release Highlights

•Reported second quarter 2026 revenue of $344 thousand during the Proteus transition period.

•Updated anticipated Proteus launch timeline to Q2 2027 to incorporate an additional integrated instrument design cycle focused on manufacturing readiness, system repeatability, and customer experience at launch.

•Highlighted an estimated $4 billion non-human proteomics market opportunity identified through on-going Platinum commercialization activities.

•Announced a reduction in force of approximately 20% of the Company’s workforce to align resources and spending with the updated Proteus launch timeline.

•Extended cash runway into Q4 2028 from Q2 2028.

“Our conviction in Proteus remains strong. Testing of our integrated instruments has generated sequencing data that reinforces our confidence in the underlying technology,” said Jeff Hawkins, president and Chief Executive Officer of Quantum-Si. “As we advanced the program, we concluded that adding an additional integrated instrument design cycle was the most responsible path to strengthen manufacturing readiness, improve system performance, and ensure a successful customer experience at launch. While this decision extends the timeline, we believe it significantly improves our readiness for commercialization and positions Proteus to create the maximum long-term value for customers, shareholders, and the broader scientific community.”

Hawkins continued, “As we continue to advance Proteus toward commercialization, our ongoing customer work is also expanding our view of the platform’s addressable markets. Over the past few months, we have been working with multiple customers applying protein sequencing to agricultural applications, pathogen detection and typing, and viral protein surveillance applications. Based on this work, we believe the non-human proteomics market opportunity for Proteus is substantial, at more than $4 billion annually and is likely to be larger as we continue to develop our understanding of additional non-human markets.”

Second Quarter 2026 Financial Results

For the second quarter of 2026, the Company recorded revenue of $344 thousand, compared to $591 thousand in the second quarter of 2025. For the six months ended June 30, 2026, the Company recorded revenue of $602 thousand, compared to $1.4 million in the prior-year period. The year-over-year decrease reflected the Company’s ongoing transition from Platinum to the anticipated Proteus platform, including lower instrument

demand, continued consumable usage by existing customers, and commercial programs intended to support customer migration to Proteus. Gross profit was $172 thousand and gross margin was 50% in the second quarter of 2026. For the six months ended June 30, 2026, gross profit was $246 thousand and gross margin was 41%, with results affected by revenue mix, timing of sales, and transition-period commercial activity.

Total operating expenses were $25.8 million for the second quarter of 2026, compared to $30.5 million for the same period in the prior year, and $49.9 million for the six months ended June 30, 2026, compared to $56.1 million for the same period in the prior year. Adjusted total operating expenses were $22.6 million for the second quarter of 2026, compared to $23.8 million for the same period in the prior year, and adjusted total operating expenses for the six months ended June 30, 2026, were $43.9 million compared to $46.6 million for the same period in the prior year. Spending levels reflected continued investment in Proteus development and commercialization readiness, partially offset by ongoing expense management.

The Company also announced cost-reduction actions, including a reduction in force affecting approximately 20% of total company headcount. The actions are expected to streamline operating expenses in connection with the revised Proteus development and launch timeline while maintaining resources for critical development, manufacturing, and commercial readiness activities. The Company expects the actions to generate approximately $12 million in annualized operating expense savings once fully implemented.

Net loss was $23.5 million for the second quarter of 2026, compared to a net loss of $28.8 million for the same period in the prior year, and net